0001209191-24-005060.txt : 20240322
0001209191-24-005060.hdr.sgml : 20240322
20240322163110
ACCESSION NUMBER: 0001209191-24-005060
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240320
FILED AS OF DATE: 20240322
DATE AS OF CHANGE: 20240322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fust Matthew K
CENTRAL INDEX KEY: 0001397266
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 24775721
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-03-20
0
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001397266
Fust Matthew K
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
1
0
0
0
1
Common Stock
2024-03-20
4
M
0
12500
23.24
A
31036
D
Common Stock
2024-03-20
4
S
0
12500
43.57
D
18536
D
Common Stock
2024-03-20
4
M
0
12500
23.23
A
31036
D
Common Stock
2024-03-20
4
S
0
12500
43.57
D
18536
D
Common Stock
2024-03-20
4
M
0
17500
20.23
A
36036
D
Common Stock
2024-03-20
4
S
0
17500
43.58
D
18536
D
Common Stock
2024-03-20
4
M
0
17500
18.29
A
36036
D
Common Stock
2024-03-20
4
S
0
17500
45.50
D
18536
D
Stock Option (right to buy)
23.24
2024-03-20
4
M
0
12500
0.00
A
2029-06-20
Common Stock
12500
0
D
Stock Option (right to buy)
23.23
2024-03-20
4
M
0
12500
0.00
A
2030-06-18
Common Stock
12500
0
D
Stock Option (right to buy)
20.23
2024-03-20
4
M
0
17500
0.00
A
2031-06-21
Common Stock
17500
0
D
Stock Option (right to buy)
18.29
2024-03-20
4
M
0
17500
0.00
A
2032-06-16
Common Stock
17500
0
D
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
/s/ Marc Wilson, as attorney-in-fact
2024-03-22